Carlsmed Revenue and Competitors

Location

#1253

Growjo Ranking

3D

Industry

Estimated Revenue & Valuation

  • Carlsmed's estimated annual revenue is currently $14.4M per year.(i)
  • Carlsmed's estimated revenue per employee is $145,960

Employee Data

  • Carlsmed has 99 Employees.(i)
  • Carlsmed grew their employee count by 38% last year.

Carlsmed's People

NameTitleEmail/Phone
1
Founder and CEOReveal Email/Phone
2
CTO, Co-founderReveal Email/Phone
3
CFOReveal Email/Phone
4
Chief StaffReveal Email/Phone
5
Chief StaffReveal Email/Phone
6
VP Quality and RegulatoryReveal Email/Phone
7
VP, US SalesReveal Email/Phone
8
VP, OperationsReveal Email/Phone
9
VP Strategic AccountsReveal Email/Phone
10
VP MarketingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M110%N/AN/A
#2
$24270M2786321%$4BN/A
#3
$3M2532%N/AN/A
#4
$5.8M39-5%N/AN/A
#5
$0.6M150%$7.5MN/A
#6
$2.9M24-17%N/AN/A
#7
$5M37N/AN/AN/A
#8
$5.2M383%N/AN/A
#9
$9.3M63-9%$122MN/A
#10
$1.8M18-5%N/AN/A
Add Company

What Is Carlsmed?

Carlsmed is transforming medicine by personalizing complex spine surgery to improve patient outcomes.

keywords:N/A

N/A

Total Funding

99

Number of Employees

$14.4M

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Carlsmed News

2022-04-17 - Carlsmed Raises $30M in Series B Funding to Scale ...

Carlsmed's mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company's aprevo® devices are...

2022-04-17 - Carlsmed backers provide $30M for personalized spinal ...

Our goal is for Aprevo to be the last spinal surgery a patient will ever need,” said Carlsmed CEO Mike Cordonnier. “Unlike conventional implants...

2022-04-17 - Carlsmed Raises $30M in Series B Funding

Carlsmed, a Carlsbad, CA-based spine surgery healthcare company, raised $30M in Series B funding. The round was led by Capital Group with...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.8M995%N/A
#2
$14.6M101-8%N/A
#3
$10.5M10320%N/A
#4
$27.2M1075%N/A
#5
N/A1094%N/A